v2.4.0.6

Investments in Variable Interest Entities (Details) (USD $) | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2012 | Sep. 30, 2011 | Dec. 31, 2011 | Sep. 30, 2012 Knopp [Member] | Sep. 30, 2011 Knopp [Member] | Sep. 30, 2012 Knopp [Member] | Sep. 30, 2011 Knopp [Member] | Sep. 30, 2012 Neurimmune [Member] | Sep. 30, 2011 Neurimmune [Member] | Sep. 30, 2012 Neurimmune [Member] | Sep. 30, 2011 Neurimmune [Member] | Dec. 31, 2010 Common Class B [Member] Knopp [Member]
Investment in Variable Interest Entities (Textual) [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of common shares in variable interest entities |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00%
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement |  |  |  |  |  |  |  | $ 255,000,000 |  |  |  | $ 345,000,000 |  |
Percentage of funding for R&D cost required in support of the collaboration agreement |  |  |  |  |  |  |  | 100.00% |  |  |  | 100.00% |  |
Research and development expense | 304,217,000 | 301,391,000 | 989,738,000 | 880,668,000 |  | 15,700,000 | 21,800,000 | 58,900,000 | 36,500,000 | 3,400,000 | 1,500,000 | 8,500,000 | 6,300,000 |
Payment recognized as a charge to noncontrolling interests, net of tax |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  | 15,000,000 |
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities | $ 9,300,000 |  | $ 9,300,000 |  | $ 14,600,000 |  |  |  |  |  |  |  |  |

X
- Definition Investment in biotechnology companies that are determined to be unconsolidated variable interest entities. + References No definition available. + Details
Name: | biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | biib_InvestmentInVariableInterestEntitiesTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment recognized as charge to noncontrolling interests net of tax. + References No definition available. + Details
Name: | biib_PaymentRecognizedAsChargeToNoncontrollingInterestsNetOfTax
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase of common shares in variable interest entities. + References No definition available. + Details
Name: | biib_PurchaseOfCommonSharesInVariableInterestEntities
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement. + References No definition available. + Details
Name: | biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development cost in support of the collaboration agreement. + References No definition available. + Details
Name: | biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration